Neurocrine Biosciences | NBIX - Market Capitalization


Neurocrine Biosciences reported $13.83B in Market Capitalization this February of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 371.63B 37.4B Feb/2026
Acadia Pharmaceuticals USD 3.6B 10M Sep/2025
Agios Pharmaceuticals USD 2.33B 402M Sep/2025
ALKERMES USD 4.95B 235M Sep/2025
Alnylam Pharmaceuticals USD 59.77B 17.25B Sep/2025
Amgen USD 184.41B 32.48B Feb/2026
Biogen USD 20.54B 2.13B Sep/2025
BioMarin Pharmaceutical USD 10.4B 142M Sep/2025
Cytokinetics USD 6.58B 2.63B Sep/2025
Dynavax Technologies USD 1.16B 26M Sep/2025
Exelixis USD 10.79B 1.79B Sep/2025
Gilead Sciences USD 137.73B 184M Sep/2025
Halozyme Therapeutics USD 8.58B 2.17B Sep/2025
Incyte USD 16.56B 3.38B Sep/2025
Ionis Pharmaceuticals USD 10.43B 4.14B Sep/2025
Neurocrine Biosciences USD 13.92B 1.48B Sep/2025
Pfizer USD 147.57B 12.48B Feb/2026
Prothena USD 473M 52M Feb/2026
Regeneron Pharmaceuticals USD 81.12B 21.53B Dec/2025
Repligen USD 7.52B 532M Sep/2025
Sarepta Therapeutics USD 2.02B 336M Sep/2025
Teva Pharmaceutical Industries USD 36.42B 14.06B Dec/2025
Ultragenyx Pharmaceutical USD 2.9B 539M Sep/2025
Vertex Pharmaceuticals USD 100.41B 13.91B Sep/2025